Cetuximab treatment alters the content of extracellular vesicles released from tumor cells

Susan M van Dommelen; Roy van der Meel; Wouter W van Solinge; Maria Coimbra; Pieter Vader; Raymond M Schiffelers

doi:10.2217/nnm-2015-0009

Cetuximab treatment alters the content of extracellular vesicles released from tumor cells

Susan M van Dommelen, Roy van der Meel, Wouter W van Solinge, Maria Coimbra, Pieter Vader, Raymond M Schiffelers

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

AIM: Extracellular vesicles (EVs) are attractive candidates for biomarker research, because their content reflects the parental cell status. This study aimed to examine whether tumor cell derived EVs mirrored the cellular changes caused by treatment with cetuximab, a therapeutic antibody that blocks activation of EGF receptor (EGFR).

MATERIALS & METHODS: A-431 cells were treated with cetuximab for 48 h. EVs were isolated using differential centrifugation and protein content was analyzed using western blotting.

RESULTS: EV levels of EGFR and phospho-EGFR were reduced after cetuximab treatment, reflecting similar changes in the parental cells. In addition, cetuximab was found associated with EVs.

CONCLUSION: EVs could serve as biomarkers to monitor cetuximab treatment. Association of cetuximab with EVs might influence its behavior.

Original language	English
Pages (from-to)	881-90
Number of pages	10
Journal	Nanomedicine (Lond)
Volume	11
Issue number	8
DOIs	https://doi.org/10.2217/nnm-2015-0009
Publication status	Published - Apr 2016

Access to Document

10.2217/nnm-2015-0009

Cite this

@article{e7ac6f98faf944269871ef50545ec735,

title = "Cetuximab treatment alters the content of extracellular vesicles released from tumor cells",

abstract = "AIM: Extracellular vesicles (EVs) are attractive candidates for biomarker research, because their content reflects the parental cell status. This study aimed to examine whether tumor cell derived EVs mirrored the cellular changes caused by treatment with cetuximab, a therapeutic antibody that blocks activation of EGF receptor (EGFR).MATERIALS & METHODS: A-431 cells were treated with cetuximab for 48 h. EVs were isolated using differential centrifugation and protein content was analyzed using western blotting.RESULTS: EV levels of EGFR and phospho-EGFR were reduced after cetuximab treatment, reflecting similar changes in the parental cells. In addition, cetuximab was found associated with EVs.CONCLUSION: EVs could serve as biomarkers to monitor cetuximab treatment. Association of cetuximab with EVs might influence its behavior.",

author = "{van Dommelen}, {Susan M} and {van der Meel}, Roy and {van Solinge}, {Wouter W} and Maria Coimbra and Pieter Vader and Schiffelers, {Raymond M}",

year = "2016",

month = apr,

doi = "10.2217/nnm-2015-0009",

language = "English",

volume = "11",

pages = "881--90",

journal = "Nanomedicine (Lond)",

issn = "1743-5889",

publisher = "Future Medicine Ltd.",

number = "8",

}

TY - JOUR

T1 - Cetuximab treatment alters the content of extracellular vesicles released from tumor cells

AU - van Dommelen, Susan M

AU - van der Meel, Roy

AU - van Solinge, Wouter W

AU - Coimbra, Maria

AU - Vader, Pieter

AU - Schiffelers, Raymond M

PY - 2016/4

Y1 - 2016/4

N2 - AIM: Extracellular vesicles (EVs) are attractive candidates for biomarker research, because their content reflects the parental cell status. This study aimed to examine whether tumor cell derived EVs mirrored the cellular changes caused by treatment with cetuximab, a therapeutic antibody that blocks activation of EGF receptor (EGFR).MATERIALS & METHODS: A-431 cells were treated with cetuximab for 48 h. EVs were isolated using differential centrifugation and protein content was analyzed using western blotting.RESULTS: EV levels of EGFR and phospho-EGFR were reduced after cetuximab treatment, reflecting similar changes in the parental cells. In addition, cetuximab was found associated with EVs.CONCLUSION: EVs could serve as biomarkers to monitor cetuximab treatment. Association of cetuximab with EVs might influence its behavior.

AB - AIM: Extracellular vesicles (EVs) are attractive candidates for biomarker research, because their content reflects the parental cell status. This study aimed to examine whether tumor cell derived EVs mirrored the cellular changes caused by treatment with cetuximab, a therapeutic antibody that blocks activation of EGF receptor (EGFR).MATERIALS & METHODS: A-431 cells were treated with cetuximab for 48 h. EVs were isolated using differential centrifugation and protein content was analyzed using western blotting.RESULTS: EV levels of EGFR and phospho-EGFR were reduced after cetuximab treatment, reflecting similar changes in the parental cells. In addition, cetuximab was found associated with EVs.CONCLUSION: EVs could serve as biomarkers to monitor cetuximab treatment. Association of cetuximab with EVs might influence its behavior.

U2 - 10.2217/nnm-2015-0009

DO - 10.2217/nnm-2015-0009

M3 - Article

C2 - 27021928

SN - 1743-5889

VL - 11

SP - 881

EP - 890

JO - Nanomedicine (Lond)

JF - Nanomedicine (Lond)

IS - 8

ER -

Cetuximab treatment alters the content of extracellular vesicles released from tumor cells

Abstract

Access to Document

Fingerprint

Cite this